Correction of azotemia in patients with chronic kidney disease

Chronic kidney disease (CKD) has become one of the most common non-infectious chronic diseases in the world. The World Health Organization predicts that CKD will become the 5th most common chronic disease in 2040. The causes of CKD are multifactorial and varied, but early symptoms are often subtle and silent. For most patients with CKD, pharmacological treatment involves a more general approach that does not depend on the nephrosclerosis. It is believed that in addition to the renoprotective effect, the issue of correcting azotemia in patients with CKD remains relevant. Azotemia is a biochemical abnormality defined as an increase or accumulation of nitro­genous products, creatinine in the blood and other secondary waste pro­ducts in the body. An increase in the level of nitrogenous wastes is associated with the inability of the renal system to adequately filter waste products. This is a typical sign of both acute kidney injury and CKD. For the correction of azotemia in patients with CKD, it is advi­sable and pathogenetically justified to use Duo­nefril® (Lespedeza capitata extract in combination with silymarin), which contains a scientifically based combination of substances of plant origin with nephroprotective properties. Duonefril® in combination with traditional approaches helps preserve and improve the filtration function of the kidneys, due to an increase in the estimated glomerular filtration rate and a hypoazotemic effect in CKD against the background of diabetes mellitus, hypertension and other kidney conditions